公开(公告)号：US08343500B2

公开(公告)日：2013-01-01

申请号：US11979224

申请日：2007-10-31

Applicant: David Cameron Wraith ,  Heather Barbara Streeter

Inventor： David Cameron Wraith ,  Heather Barbara Streeter

IPC: A61K38/04 ,  A61K38/00 ,  A61K39/00 ,  C07K2/00 ,  C07K4/00 ,  C07K5/00 ,  C07K7/00 ,  C07K14/00 ,  C07K16/00 ,  C07K17/00

CPC classification number: A61K39/0008 ,  C07K14/4713 ,  G01N33/505

Abstract: There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a method to treat and/or prevent a disease. The present invention also relates to a composition which comprises the following myelin basic protein (MBP) peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.

Abstract translation: 提供了通过选择能够结合MHC I类或II类分子而不进一步加工的肽来选择耐受性肽的方法。 还提供了通过这种方法选择的肽及其在药物组合物中的用途和治疗和/或预防疾病的方法。 本发明还涉及包含以下髓鞘碱性蛋白（MBP）肽的组合物：MBP 30-44; MBP 83-99; MBP 131-145; 和MBP 140-154。 该组合物可用于治疗疾病，特别是多发性硬化症和/或光学神经炎，本发明还涉及这些用途和方法。

公开(公告)号：US20080200368A1

公开(公告)日：2008-08-21

申请号：US11979224

申请日：2007-10-31

Applicant: David Cameron Wraith ,  Heather Barbara Streeter

Inventor： David Cameron Wraith ,  Heather Barbara Streeter

IPC: A61K38/02 ,  C07K2/00

CPC classification number: A61K39/0008 ,  C07K14/4713 ,  G01N33/505

Abstract: There is provided a method for selecting a tolerogenic peptide by selecting a peptide which is capable of binding to an MHC class I or II molecule without further processing. There is also provided a peptide selected by such a method and its use in a pharmaceutical composition and a method to treat and/or prevent a disease. The present invention also relates to a composition which comprises the following myelin basic protein (MBP) peptides: MBP 30-44; MBP 83-99; MBP 131-145; and MBP 140-154. The composition may be used to treat a disease, in particular multiple sclerosis and/or optical neuritis and the invention also relates to such uses and methods.

Abstract translation: 提供了通过选择能够结合MHC I类或II类分子而不进一步加工的肽来选择耐受性肽的方法。 还提供了通过这种方法选择的肽及其在药物组合物中的用途和治疗和/或预防疾病的方法。 本发明还涉及包含以下髓鞘碱性蛋白（MBP）肽的组合物：MBP 30-44; MBP 83-99; MBP 131-145; 和MBP 140-154。 该组合物可用于治疗疾病，特别是多发性硬化症和/或光学神经炎，本发明还涉及这些用途和方法。

公开(公告)号：US07071297B2

公开(公告)日：2006-07-04

申请号：US10900032

申请日：2004-07-27

Applicant: David Cameron Wraith ,  Heather Barbara Streeter ,  Mary Ponsford ,  Graziella Mazza

Inventor： David Cameron Wraith ,  Heather Barbara Streeter ,  Mary Ponsford ,  Graziella Mazza

IPC: A61K38/00 ,  A61K38/08

CPC classification number: C07K14/4713 ,  A61K38/00

Abstract: There is provided a peptide that is capable of binding to an MHC class I or II molecule without further processing (i.e., an apitope), which comprises a portion of the region 131-158 of myelin basic protein. In particular, there is provided an apitope which is selected from the following myelin basic protein peptides: 134-148, 135-149, 136-150, 137-151, 138-152, 139-153, 140-154.There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide.

Abstract translation: 提供了能够结合MHC I类或II类分子而不进一步加工的肽（即，核苷酸），其包含髓磷脂碱性蛋白质131-158区域的一部分。 特别地，提供了选自以下髓鞘碱性蛋白质肽的核苷酸：134-148,135-149,136-150,137-151,138-152,139-153,140-154。 还提供了这样的肽在药物组合物中的应用以及使用这种肽治疗和/或预防疾病的方法。